OR WAIT 15 SECS
© 2020 MJH Life Sciences and BioPharm International. All rights reserved.
Jill Wechsler is BioPharm International's Washington Editor, firstname.lastname@example.org.
July 24, 2020
Patient advocates, research experts, and industry are calling for more user fee revenues to support CBER programs to advance innovative therapies.
July 21, 2020
Should therapies and vaccines be cheap or free in a pandemic and would that really dry up innovation?
July 20, 2020
Industry should be seeking more information from FDA on how it will restart its current inspection program.
July 09, 2020
FDA officials are moving to clarify standards and requirements for vetting and approving viable preventives.